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Objectives. This cross-sectional study investigated the influence of clinically diagnosed neuropathy (cdNP) on respiratory muscle
strength in patients with type 2 diabetes mellitus (T2DM). Methods. 110 T2DM patients and 35 nondiabetic healthy controls
(≥60 years) were allocated to one of three groups depending on the presence of cdNP: T2DM without cdNP (D−; n = 28),
T2DM with cdNP (D+; n = 82), and controls without cdNP (C; n = 35). Clinical neurological diagnostic examination consisted
of Vibration Perception Threshold and Diabetic Neuropathy Symptom score. Respiratory muscle strength was registered by
maximal Inspiratory and Expiratory Pressures (PImax and PEmax), and respiratory function by Peak Expiratory Flow (PEF).
Isometric Handgrip Strength and Short Physical Performance Battery were used to evaluate peripheral skeletal muscle strength
and physical performance. Univariate analysis of covariance was used with age, level of physical activity, and body mass index as
covariates. Results. PImax, PEmax, and PEF were higher in C compared to D− and D+. Exploring more in detail, PImax, PEmax,
and PEF were significantly lower in D+ compared to C. PEmax and PEF were also significantly lower in D− versus C. Measures
of peripheral muscle strength and physical performance showed less associations with cdNP and T2DM. Conclusions. The
presence of cdNP affects respiratory muscle strength in T2DM patients compared to healthy controls. Both cdNP and diabetes
in themselves showed a distinctive impact on respiratory muscle strength and function; however, an accumulating effect could
not be ascertained in this study. As commonly used measures of peripheral muscle strength and physical performance seemed
to be less affected at the given time, the integration of PImax, PEmax, and PEF measurements in the assessment of respiratory
muscle weakness could be of added value in the (early) screening for neuropathy in patients with T2DM.
1. Introduction
Type 2 diabetes mellitus (T2DM) is the most common cause
of (sensori) motor and autonomic neuropathy [1, 2]. One of
the most important and well-recognized clinical manifesta-
tions of diabetes-associated neuropathy (NP) is impairment
and debilitation in functioning and locomotion due to the
development of lower limb skeletal muscle weakness, which
is closely related to the severity of NP [3, 4]. Studies using
magnetic resonance imaging (MRI) showed accelerated mus-
cle atrophy in accordance with an increased loss of muscle
strength in patients with T2DM suffering from symptomatic
NP in comparison to T2DM patients without NP and healthy
controls [5, 6].
For that matter and from a clinical point of view, the
assessment of the influence of NP on muscle function is
highly recommended and mainly achieved by means of
standardized clinical examinations such as manual muscle
testing, isometric and isokinetic dynamometry, Handgrip
Strength (HGS), and by functional performance tools (e.g.,
timed chair stand test (CST) and indirectly by gait analysis
and appraisal) [5, 7–9].
Approximately 10–15% of all people aged >40 suffers
from NP in which diabetes remains the most common cause.
Asides age, diabetes and a set of other distinctive factors
causing NP has to be classified as idiopathic in 20–30% of
all patients suffering from NP even after thorough investiga-
tion. This idiopathic NP is considered as a major culprit of a
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person’s disability with important social impact due to pain,
gait instability, increased risk of falls, injuries, and poor
quality of life [10–12].
The association between reduced respiratory function
and T2DM has already been described [13], however, the
underlying mechanisms are still undisclosed. Klein et al.
reported in a systematic review an inverse association
between respiratory function on the one hand and blood
glucose levels, the severity and duration of T2DM on the
other, independent of smoking status or presence of obesity
[14]. van den Borst et al. also reported a decreased lung func-
tion in T2DM. Metaregression analysis showed, however,
that this relation could not be explained by body mass index
(BMI), smoking, diabetes duration, or glycated hemoglobin
(HbA1c) [15]. Respiratory muscle strength is strongly associ-
ated with pulmonary function and may play important roles
in the respiratory network, which on its turn depends on
intact neural circuitry that orchestrates the interplay between
respiratory muscles and intrinsic pulmonary function to
maintain adequate ventilation [16]. Kabitz et al. showed that
impaired respiratory neuromuscular function, which is
strongly related to diabetic polyneuropathy, occurs in T2DM
patients as assessed by nonvolitional gold-standard phrenic
nerve stimulation [4]. Also, other studies have reported that
in patients with T2DM, respiratory muscle weakness can
occur and might be associated with autonomic dysfunction
[17, 18]. In contrast to the large number of studies examin-
ing peripheral muscle weakness in T2DM patients with NP
[3, 5, 8, 19–22], only limited research has been conducted
regarding the impact of diabetic—or any kind for that
matter—NP on respiratory muscle strength [4].
The aim of the present study is to evaluate respiratory
muscle strength and function in T2DM patients with clini-
cally diagnosed neuropathy (cdNP) and to compare this with
T2DM patients without cdNP and healthy controls. We
hypothesize that, compared to healthy controls, respiratory
muscle strength and function are decreased in T2DM
patients without cdNP and even more impaired in the
presence of cdNP.
With respect to the aforementioned hypothesis, the
assessment of maximal static Inspiratory and Expiratory
Pressure measurements and Peak Expiratory Flow could be
considered regarding its added value in the screening for NP.
2. Materials and Methods
2.1. Study Design and Population. In this cross-sectional
case-control study, 110 patients with T2DM and 35 healthy
controls were included (n = 145).
Participants comprised both community-dwelling elderly
and elderly living in a residential care setting. Patients with
T2DM were recruited by the Department of Endocrinology
(University Hospital Ghent) and their general practitioner,
and healthy controls by online advertising and flyer distribu-
tion. T2DM was diagnosed on two different occasions based
on HbA1c assessments according to the Type 2 Diabetes
ADA Diagnosis Criteria [23].
Criteria for inclusion were (i) aged 60 years or more, (ii)
living in the community or residential care setting, (iii) able
to respond adequately to Dutch instructions, and (iv) able
to walk independently with or without walking aids. Subjects
suffering from (i) major neurological conditions (e.g., stroke,
Parkinson’s disease, and dementia), (ii) musculoskeletal dis-
abilities (e.g., foot ulcerations, lower extremity amputations,
and arthritis with limited joint mobility precluding ambula-
tion), (iii) severe cardiovascular disorders (e.g., exercise-
induced chest pain, congestive heart failure (New York Heart
Association class III and IV)), and (iv) respiratory diseases
(e.g., exercise-induced asthma and COPD (Global Initiative
for Chronic Obstructive Lung Diseases (GOLD)) stages 3
and 4) were excluded.
Based on a clinical neurological diagnostic examination
performed by trained physical therapists, the population
could be divided into three groups: T2DM without cdNP
(D−; n = 28), T2DM with cdNP (D+; n = 82), and nondia-
betic healthy controls without cdNP (C; n = 35). Control sub-
jects having NP after the clinical neurological examination
were excluded as the differentiating etiology of NP was not
further examined.
The Ethical Committee of the Ghent University Hospital
gave approval to this study, and all participants signed an
informed consent. Consequently, this research is compliant
with the World Medical Association Declaration of
Helsinki – Ethical Principles for Medical Research Involving
Human Subjects.
2.2. Outcome Measurements. All measurements were per-
formed on a single morning in a quiet setting and well-lit
room with flat surface. At first, anthropometrical data and
HbA1c were obtained followed by NP-examinations. Subse-
quently, respiratory muscle strength, HGS, and the Short
Physical Performance Battery (SPPB) were assessed, and a
physical activity questionnaire was completed.
2.3. Patient Characteristics. Height, weight, BMI, and body
composition (bioelectrical impedance analysis; BIA, Body-
stat® 1500MDD) were measured and calculated.
HbA1c was measured using the A1CNow SELFCHECK®
(Bayer), an instrument which is well correlated with stan-
dardized laboratory HbA1c tests (r = 0 758) [24].
Habitual physical activity levels were measured using the
physical activity questionnaire for the elderly [25, 26].
2.4. Measurements of Peripheral Clinically Diagnosed
Neuropathy. The clinical neurological diagnostic examina-
tion consisted of two parts: measurements of the Vibration
Perception Threshold (VPT), an assessment of the peripheral
large-fiber sensory nerve function, and the Diabetic Neurop-
athy Symptom score questionnaire (DNS).
The VPT, a valid and reliable measurement, was deter-
mined using a Bio-Thesiometer® (Bio Medical Instrument
Co., Ohio, USA) on the left and right medial malleolus and
on the distal plantar surface of the big toes [27, 28]. VPT
was defined as the lowest recorded voltage when subjects
indicated the sense of vibration. Each measurement was
repeated three times and the lowest reading was considered
[29, 30]. Since the threshold at which vibration becomes
perceptible is dependent of age, gender, and location, four
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percentile rank charts of VPT variation were used [29]. To
decide whether vibration perception was within the normal
range, a normality cut-off on the 95th percentile was applied.
If one of the readings (big toe and the medial malleolus, both
left and right) was above the 95th percentile, this criterion
was classified as positive.
The DNS, a validated 4-point yes/no questionnaire, has a
high predictive value in the screening for diabetic NP when
patients score ≥1/4. Meijer et al. compared the validity,
predictive value, and reproducibility of the DNS with the
Neuropathy Symptom Score (NSS). They found a high corre-
lation between NSS and DNS score (r = 0 88) and concluded
that the DNS is a fast, easy, reproducible (Cohen’s weighted
kappa 0.78–0.95), and valid assessment tool to screen for
diabetic polyneuropathy [31].
Patients with T2DM were classified as having peripheral
cdNP based on at least one of two positive criteria: a VPT
exceeding the normality cut-off of 95% or a DNS score
of ≥1/4.
2.5. Measurements of Muscle Strength. The maximal static
Inspiratory and Expiratory Pressure measurements (PImax
and PEmax; cm H2O) were obtained by a Pocket-Spiro Mouth
Pressure Monitor with a differential pressure transducer
(MPM100; Medical Electronic Construction®). To measure
PImax, subjects were seated and asked to exhale slowly and
completely up to residual volume and then to perform a
maximum inspiratory maneuver during at least 1.5 seconds
against a completely occluded airway. Then, a 1-second aver-
age including the peak pressure was calculated, indicating the
inspiratory muscle strength. PEmax was determined under the
same conditions while first inhaling completely up to total
lung capacity and then performing a maximum expiratory
maneuver. For each index, three tests were recorded, and
the highest value was used for data analysis [32–35]. The
measurement of the maximum static mouth pressures
produced against an occluded airway is the most widely used
method of measurement and is an easy way to gauge respira-
tory muscle strength and to determine the severity of respira-
tory muscle strength impairments [36]. Additionally, Peak
Expiratory Flow (PEF; L/m), a cheap, simple, and widely
accessible technique with a prognostic value for morbidity
[37, 38], was recorded using a Mini-Wright Peak Flow Meter
(Henrotech®). This is internationally recognized as the
golden standard for PEF measurements [39]. PEF is used as
an indicator for respiratory muscles strength in subjects
without lung disorders [37].
Isometric HGS (kg) was measured according to the
American Society of Hand Therapists guidelines [40] using
the Jamar® dynamometer (Sammons Preston Rolyan Inc.,
Bolingbrook, IL) at the dominant side [37]. The highest grip
score of three consecutive trials was retained.
2.6. Measurements of Physical Performance. The SPPB
consists of a timed standing balance test (feet together side-
by-side, semitandem, and tandem stance), a walk test (time
to walk 2.44 meters at usual pace), and a CST (time to raise
from a chair and return to the seated position in five times)
[41]. Each of the three component tasks was rated from 0
(unable to complete) to 4 (best), and a compiled score was
computed by the sum of scores on component tasks (range
0=worst to 12= best) [42, 43]. This composite test is often
used and validated as a standard assessment of physical
performance in research and clinical practice of the ageing
population [37, 44].
2.7. Statistical Analysis. Data were analyzed using IBM
Statistical Package for Social Sciences (SPSS version 24 for
Windows) and were considered significant at α < 0 05. After
confirming the approximate normality of data using the
Shapiro–Wilk test, descriptive statistics for anthropometric,
biochemical, and respiratory muscle parameters are pre-
sented by arithmetic mean (standard deviation; SD), median
(min-max), and by ratio (% and count). Between-groups
analysis was performed using univariate analysis of covari-
ance (ANCOVA) with age, level of physical activity, and
BMI as covariates. Post hoc comparisons were corrected with
the Bonferroni test. A Pearson chi-square test was used for
gender and residential status in order to detect all between-
group differences.
Linear regression analysis between VPT, DNS, and
HbA1c on the one hand and measures of respiratory muscle
strength and function (i.e., PImax, PEmax, and PEF) on the
other was performed with age as confounder.
3. Results
Subject characteristics are shown in Table 1. The healthy
control group (C) was significantly younger (F = 3 487;
p = 0 017), had lower BMI (F = 3 561; p = 0 015), was more
physically active (F = 5 343; p = 0 002), and proportionally
a minority was living in a residential setting (p = 0 002) com-
pared to the other groups. There was no significant difference
in gender distribution between the 3 groups (p = 0 587).
HbA1c levels were significantly higher in the diabe-
tes groups compared to the control group (F = 24 894;
p < 0 001), but showed no significant differences between the
diabetes groups (D− vs. D+). Also, no significant between-
group differences were found for duration of diabetes.
VPT-toe measures (left versus right) and VPT-ankle
measures in the C, D−, and D+ are presented in Table 2.
The actual values of DNS reveal a score of zero on the
scale of 0–4 in C in contrast with D+ (Table 3).
Linear regression analysis between VPT, DNS, and
HbA1c on the one hand and measures of respiratory muscle
strength and function (i.e., PImax, PEmax, and PEF) on the
other has been performed. Age was considered as a con-
founder since this is the single covariate strongly related to
respiratory function, which is less so for the level of physical
activity and BMI. The linear regression analysis on respira-
tory muscle strength (i.e., PImax and PEmax) shows that the
VPT scores are the only significant explanatory values for
the variances, respectively, in PImax (8.2%) and PEmax
(10.9%). Analyzing respiratory function (i.e., PEF), VPT
(2.8%), Hb1Ac (5.5%), and age (17.5%) significantly explain
25.8% of the variance in PEF. The outcome data are docu-
mented in Table 4.
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Table 5 reports on the assessment of respiratory muscle
strength between the three groups, corrected for age, physical
activity, and BMI. Significant differences were observed for
PImax, PEmax, and PEF. Post hoc analyses revealed significant
lower values in D+ compared to C for PImax (p = 0 005),
PEmax (p = 0 001), and PEF (p < 0 001). When comparing
D− with C, only PEmax (p = 0 039) and PEF (p = 0 026)
were significantly lower.
Functional assessment data (i.e., HGS and SPPB)
between the three groups are presented in Table 6, corrected
for age, physical activity, and BMI.
HGS revealed no between-groups differences (F = 2 100;
p = 0 128). Statistically significant differences were observed
on both the SPPB total (F = 7 209; p = 0 001) as in its subdo-
mains; CST (F = 4 533; p = 0 013), balance (F = 3 835;
p = 0 025), and gait (F = 4 130; p = 0 019) with better perfor-
mance in favor of C. For SPPB total and SPPB gait, post hoc
analysis revealed significant higher values in C compared to
D− (p = 0 008 and p = 0 043, respectively) and D+
(p = 0 002 and p = 0 031, respectively). CST and balance sub-
domains showed significant better scores for C compared to
D+ (p = 0 010 and p = 0 028, respectively). Considering SPPB
balance, only tandem stance showed significant higher
results comparing C to D+ (p = 0 019).
4. Discussion
The present study was conducted to investigate respiratory
muscle strength and function in T2DM and its relation to
NP by comparing PImax, PEmax, and PEF between T2DM
patients with cdNP, T2DM patients without cdNP, and
healthy controls.
The key findings of this study were lower measures of
PImax, PEmax, and PEF in the D− and D+ groups compared
to C.
Looking more in detail to the results, all three respiratory
muscle outcomes were significantly lower when comparing
D+ toC; PEmax andPEFwere significantly lower inD− andD+
compared to C. Herewith, it seems that the presence of
Table 2: VPT scores.
VPT: highest voltage of the left versus right toe
C (n = 34) D− (n = 26) D+ (n = 74)
Means (SD) 20.2 (5.54) 20.3 (6.04) 37.5 (12.26)
min-max 10–38 10–34 10–50
VPT: highest voltage of the left versus right ankle
C (n = 34) D− (n = 26) D+ (n = 70)
Means (SD) 23.6 (6.50) 24.0 (7.36) 40.6 (11.60)
min-max 12–35 10–45 7–50
Data were expressed as mean (SD) and minimum-maximum (min-max);
VPT: Vibration Perception Threshold; C: healthy controls; D−: T2DM
without cdNP; D+: T2DM with cdNP.
Table 3: DNS scores.
C (n = 26) D− (n = 22) D+ (n = 70)
Means (SD) 0 (0) 0 (0) 1.4 (1.35)
Median (min-max) 0 (0-0) 0 (0-0) 1 (0–4)
Data were expressed as mean (SD) and median (minimum-maximum);
DNS: Diabetic Neuropathy Symptom score; C: healthy controls; D−: T2DM
without cdNP; D+: T2DM with cdNP.
Table 4: Linear regression analysis between VPT, DNS, HbA1c and
age on one hand, and PImax, PEmax and PEF on the other.
PImax PEmax PEF




Adjusted R square 0.082 0.109 0.258
p values p = 0 003 p = 0 001 p < 0 001
PImax: Maximum Inspiratory Pressure; PEmax: Maximum Expiratory
Pressure; PEF: Peak Expiratory Flow; VPT: Vibration Perception
Threshold; HbA1c: glycated hemoglobin.
Table 1: Subject characteristics.
C (n = 35) D− (n = 28) D+ (n = 82)
Age (yrs) 73 (6.8) 79 (9.9) 79 (9.1)a
BMI (kg/m2) 28 (4.0) 31 (6.2)a 29 (5.3)
HbA1c (%) 5.5 (0.40) 6.7 (0.81)a 6.7 (1.24)a
Diabetes duration (yrs) / 10.5 (8.34) 10.3 (8.64)
Level of physical activity 8.2 (1.24–32.19) 6.4 (0.00–38.35) 2.6 (0.00–36.41)ab
Male : female
(%) 43 : 57 39 : 61 34 : 66
(count) 15 : 20 11 : 17 28 : 54
Community-dwelling : RCS
(%) 71 : 29 29 : 71a 37 : 63a
(count) 25 : 10 08 : 20a 30 : 52a
Data were expressed as mean (SD), with exception for the level of physical activity as median (min-max), gender, and residential status as ratio (% and count);
C: healthy controls; D−: T2DM without cdNP; D+: T2DM with cdNP; yrs: years; RCS: residential care setting; HbA1c: glycated hemoglobin; ap < 0 05
compared to C; bp < 0 05 compared to D−.
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NP as well as T2DM has an impact on respiratory muscle
outcome. However, an accumulating effect of cdNP and
T2DM could not be ascertained.
A posteriori power calculation on respiratory muscle
strength and function (PImax, PEmax, and PEF) resulted in a
power of 0.826, 0.912, and 0.927, respectively.
To understand our NP-related results, the innervation of
the respiratory muscles should be explored in depth. While
breathing in, the inspiratory muscles contract by recruiting
nonvolitional spinal nerves C3, C4, and C5 (the phrenic
nerve) innervating the diaphragm, cranial nerve XI, spinal
nerves C1 and C2 innervating the sternocleidomastoid and
the scalene muscles, and T1 to T12 for the external intercos-
tal muscles. The two expiratory muscle groups (the internal
intercostals and abdominals) are usually not used during
quiet breathing but are essential in performing expulsive
efforts, including cough, vomiting, and defecation. Due to
their character, these expiratory muscles are of utmost
importance during forced expiration (such as in PEmax and
PEF, during static and dynamic trunk control, and Valsalva
maneuvers). The internal intercostal muscles are innervated
by the spinal nerves T1 to T12 and the abdominals by spinal
nerves T7 to L1.
The respiratory muscles are generally controlled by
the respiratory centers of the autonomic nervous system
in the pons and medulla oblongata and are depending
on intact motor nerve supply, comparable to all skeletal
muscles [45, 46].
Kabitz et al. used bilateral anterior magnetic phrenic
nerve stimulation whereby the cortical motor command
was bypassed in order to assess respiratory neuromuscular
function related to diabetic poluneuropathy in patients with
T2DM [4]. They provided the first data regarding cdNP
and concluded that cdNP was associated with substantially




C (n = 35) D− (n = 28) D+ (n = 82)
PImax (cm H2O)
F = 5 289
p = 0 007 64.5 (28.83) 40.7 (25.22) 36.6 (23.71)
a
PEmax (cm H2O)
F = 6 785
p = 0 002 100.6 (29.58) 69.5 (29.97)
a 65.2 (31.20)a
PEF (L/min)
F = 10 600
p = 0 001 471.2 (132.27) 330.9 (152.07)
a 314.5 (221.26)a
Data were expressed as mean (SD); C: healthy controls; D−: T2DM without cdNP; D+: T2DM with cdNP; PImax: Maximum Inspiratory Pressure; PEmax:
Maximum Expiratory Pressure; PEF: Peak Expiratory Flow; ap < 0 05 compared to C.
Table 6: Univariate analysis of covariance (ANCOVA, corrected for age, body mass index, and physical activity) on peripheral muscle
strength, balance, and gait.
F value
p value
C (n = 35) D− (n = 28) D+ (n = 82)
HGS (kg)
F = 2 100
p = 0 128 26.9 (12.36) 20.1 (10.15) 17.6 (9.50)
SPPB: total
F = 7 209
p = 0 001 11 (4–12) 7 (1–12)
a 6 (1–12)a
(A) CST
F = 4 533
p = 0 013 3 (0–4) 1 (0–4) 0 (0–4)
a
(B) Balance total
F = 3 835
p = 0 025 4 (3–4) 3.5 (0–4) 3 (0–4)
a
Side-by-side
F = 0 508
p = 0 603 2 (2-2) 2 (0–2) 2 (0–2)
Semitandem
F = 1 334
p = 0 268 2 (2-2) 2 (0–2) 2 (0–2)
Tandem
F = 3 966
p = 0 022 2 (1-2) 1.5 (0–2) 1 (0–2)
a
(C) Gait
F = 4 130
P = 0 019 4 (1–4) 2 (1–4)
a 3 (1–4)a
Data were expressed as median (min-max), with exception for HGS as mean (SD); C: healthy controls; D−: T2DM without cdNP; D+: T2DM with cdNP;
HGS: Handgrip Strength; SPPB: Short Physical Performance Battery; CST: chair stand test; ap < 0 05 compared to C.
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impaired respiratory neuromuscular function in patients
with T2DM, when stimulating the nonvolitional phrenic
nerve. No alterations in respiratory function could be found
when assessing volitional respiratory muscle strength. The
volitional respiratory neuromuscular function testing was
performed by using PImax, PEmax, and maximal sniff pres-
sures. PEF, however, was not assessed in this particular study.
The exclusion criterion used by Kabitz et al. consisted in the
diabetic group of known primary lung diseases, whereas in
the control group healthy male subjects experiencing lung,
cardiac, or metabolic diseases were excluded [4]. The differ-
ent eligibility criteria between the research of Kabitz et al.
and our own study could explain the different results. We
opted for stricter selection criteria such as exclusion of
patients with exercise-induced asthma and COPD GOLD
stages 3 and 4. It is also of importance to mention the lower
mean age of their controls (60.3 years± 6.9) and the diabetic
patients (63.6 years± 7.5) compared to the present study,
which could explain the differences in outcome of the
volitional tests on respiratory neuromuscular function [47].
To understand the impact of T2DM as such, we have to
focus on muscle mass, muscle fiber type distribution, and
vascularization. Checking on the muscle fiber type distribu-
tion of the diaphragm in healthy humans, the mean relative
occurrence of slow-twitch fibers (type I) is approximately
50%. The remaining proportion is equally divided into two
different fast-twitch fibers (type IIa and IIx). Both the inspi-
ratory and expiratory intercostal muscles have at least 10%
more type I fibers than the diaphragm and most other
skeletal muscles, whereas the expiratory internal intercostal
muscles show an almost complete absence of type IIx
fibers [46].
In healthy humans, all muscle fibers are surrounded by a
certain number of capillaries, depending on their fiber type.
In the diaphragm, type I fibers are surrounded by 4–6 capil-
laries per fiber, whereas slightly less [3–5] are found around
type IIa and IIx fibers. However, the calculated values for
the fiber area surrounded by each capillary are smaller in
the diaphragm than in lower or upper limb muscles. In the
expiratory intercostal muscles, more capillaries are found
around both type I and type IIa fibers [5, 6] compared to
the inspiratory intercostal muscles [4, 5, 46].
In the elderly in general and/or older T2DM patients,
abnormalities in muscle morphology have been observed
[48, 49]. Studies examining ageing and “accelerated” ageing
in the older T2DM patients showed a reduced muscle mass
and a decrease in muscle fiber size and number compared
to younger controls [50–52]. Fiber size differences, partic-
ularly in the type II muscle fibers, seemed to be evident
between healthy young men, healthy older men, and older
age-matched T2DM patients, suggesting that type II fibers
are more prone to muscle atrophy in the latter groups.
When examining muscle capillary density (as a parameter
of microvascular function), capillaries tended to be less
prevalent in the elderly and/or older T2DM patients,
implicating lower muscle capillary density. Dilation of
these small capillaries could explain the observed shift in
the distribution of vessel size with a relative loss of small
vessels [52].
Measures of peripheral muscle strength (HGS) and func-
tional performance (SPPB total with CST, balance, and gait
as assessment tools) showed a similar profile as the respira-
tory muscle strength assessments; i.e., C scored better
compared to D− and D+.
Analysis of the peripheral muscle strength showed no
significant difference in HGS.
SPPB total, showed a significant difference (p = 0 001),
mainly allocated to gait (usual gait speed over 2m44;
p = 0 019) since both post hoc analyses showed significant
differences of C versus D+ and D−. Walking is a complex
motor skill, involving interactions between sensory andmotor
attributes, but is essentially supported by appropriate muscle
strength and balance. Our findings regarding both strength
impairment (CST, p = 0 013) and total balance changes
(p = 0 025) with its subtest “tandem stance” (p = 0 022)
endorse the earlier research results inT2DMand cdNPon gait
[53]. The argument that gait performance could be influenced
by T2DM alone (without NP) has to be taken into consider-
ation based on previous findings [2, 9]. van Sloten et al. sug-
gested that walking in subjects with T2DM was strongly
associated with peripheral NP and decreasedmuscle strength.
This associative result could not be established in our study
when T2DM patients were compared to controls [9]. It could
be hypothesized that T2DM as such has the same detrimental
effects as the presence of cdNP in T2DM on a functional
capacity (SPPB total and gait).
Based on our data, we can but conclude that both T2DM
and NP significantly influence respiratory muscle strength
and function. It was, however, not possible to distinct the
initial cause (i.e., neuropathic respiratory impairments or
diabetes-related pathology) of decreased respiratory muscle
strength and function in our T2DM population.
The linear regression analysis on respiratory muscle
strength (i.e., PImax and PEmax) suggests that the VPT scores
are the only significant explanatory values (respectively, 8.2%
and 10.9% of the variances in PImax and PEmax) rather than
HbA1c, age, and DNS. These results indicate that VPT scores
have a larger impact on respiratory muscle strength, support-
ing the hypothesis that respiratory muscle weakness is due to
NP. Analyzing respiratory function (i.e., PEF), VPT (2.8%),
Hb1Ac (5.5%), and age (17.5%) significantly explain 25.8%
of the variance in PEF. Skloot provided evidence that the age-
ing process, in the absence of lung disease, alters the intrinsic
structure of the lung (changes in collagen fiber network) as
well as the supportive extrapulmonary structures (decreased
chest wall compliance, reduced curvature of the diaphragm,
and loss of respiratory muscle mass). These age-related
changes in respiratory mechanics lead to a reduction in
expiratory flow and lung volumes and affect lung function
[47]. An explanation of the higher impact of HbA1c com-
pared to the VPT scores can be found in the association
between increased chronic glycemic exposure to the lung
parenchyma and reduced pulmonary function in patients
with T2DM [54].
The fact that all existing screening tools and question-
naires only rely on the measurements of appendicular mus-
cles, and based on our results, it should be taken into
consideration to integrate PImax, PEmax, and PEF in the
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screening for respiratory muscle weakness as an indication
for the presence of NP in diabetic patients [33]. These find-
ings are supported by Lecube et al. [54] claiming that specific
cost-effective screening programs for lung impairment, per-
formed by health care providers, should be investigated in
further research.
In the clinical practice of a general practitioner, measure-
ments of lung function (forced vital capacity, forced expired
volume after 1 second, Tiffeneau index, and PEF) are already
regularly applied, mainly in order to detect COPD or other
related respiratory disorders. Additional evaluations of respi-
ratory muscle outcomes, which are easy to manage and have
low cost impact (e.g., a portable Peak Flow Meter), could be
of additional value and of importance in the screening for
NP in the T2DM population.
Overall, impairments of respiratory muscle strength and
function (PImax, PEmax, and PEF) were slightly more pro-
nounced compared to those of peripheral muscle strength.
Since this study had a cross-sectional design, it was not pos-
sible to draw any conclusions concerning the timing of the
impact on respiratory or peripheral muscles.
The participants were not questioned concerning smok-
ing condition and alcohol consumption, although this infor-
mation could have an impact on lung function in general,
more specific PEF values, and on peripheral NP. However,
due to a large group of respiratory disorders (asthma and
COPD GOLD stages 3 and 4) were implemented as exclusion
criterion, the impact of lung diseases on PImax, PEmax, and
PEF was significantly reduced. Regarding alcohol consump-
tion, no data were collected which could affect peripheral
NP as well. Besides, interviewing subjects about their smok-
ing and drinking habits often lead to ambiguous answers
out of exclusion fear.
The cross-sectional design limits drawing conclusions
regarding the timing of the impact of causative variables
on outcome parameters. Consequently, future research
focus on both longitudinal research and the evolution of
physical markers and symptoms such as—in this particular
study—onset of diabetes, NP, and respiratory and peripheral
muscle weakness.
It stands to reason that 82 out of 110 diabetic patients
(74.5%) were allocated to the NP group (D+) known as one
of the major comorbidities in T2DM patients [1, 2, 55].
Firstly, it is worth mentioning that according to Andersen
et al. the prevalence of cdNP increases from 8% in newly
diagnosed patients to >40% after 10 years of diabetes [3]. In
the present study, the mean duration of diabetes was above
10 years from onset in both D− and D+ groups.
Secondly, the enrolled patients with T2DM showed
higher mean age, higher BMI, and lower levels of physical
activity compared to controls. Ageing is a well-known
nonmodifiable factor for the development of diabetes and
lower muscle strength [50]. BMI has a negative impact
on muscle strength in a population with insulin resistance
(prediabetic situation) and diabetes type 2, which will
manifest itself as a decrease of absolute and relative peak
torque [56, 57]. Concerning physical activity, low levels
have a negative impact on the development of diabetes
and on lower muscle strength [57]. In our ANCOVA we
encountered this barrier by adding age, BMI, and physical
activity to add them as covariates.
Finally, peripheral cdNP was diagnosed by VPT in com-
bination with DNS with a deficient comprehensive neurolog-
ical examination. Hence, we strongly recommend the use of
the Michigan Neuropathy Screening Instrument in future
research in order to allocate T2DM patients with/without
NP more accurately to the respective groups [58–60]. In
addition to these clinical assessments, MRI can be used in
the detection of symptomatic NP, and nerve conduction
investigations can be performed by means of electroneuro-
myography to evaluate sensory action potential amplitude
and sensory and motor conduction velocity to confirm
the presence and the severity of NP [61]. The main draw-
backs to MRI and ENMG techniques are the high costs
regarding the number of participants (initially 190) and the
subject discomfort.
5. Conclusions
Based on a substantial population, this research, focusing on
respiratory muscle strength, could conclude that this strength
is negatively influenced in T2DM patients with and without
peripheral neuropathy. A summation effect in patients with
diabetes and neuropathy could not be ascertained. Screening
for this muscle characteristic may add value to daily clinical
practice of T2DM patients in assessment and follow-up.
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